from L. Silvia Munoz-Price, and John P. Quinn writing in Emerging Trends in Antibacterial Discovery: Answering the Call to Arms:
We summarize the epidemiology, clinical presentation, and current treatment options for the most clinically relevant multidrug resistant Gram-positive and Gram-negative organisms. Additionally, we describe the challenges faced by pharmaceutical companies within the antimicrobial research and development field, especially the disproportion between the degree of investment (both monetary and time) required and the relatively small profit antimicrobial agents bring. Finally, some potential solutions for the lack of antimicrobial agents are discussed. These include more widespread use of the Orphan Drug Act, patent extensions, and the Biomedical Advanced Research and Development Authority (BARDA).
Further reading: Emerging Trends in Antibacterial Discovery: Answering the Call to Arms